News Search Results
Apr 29, 2025, 06:15 ET Epson Robots to Showcase New High-Performance Automation Solutions and SafeSense Technology at Automate 2025
of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For
More news about: Epson America, Inc.
Apr 29, 2025, 06:00 ET Stealth BioTherapeutics Announces Delay in FDA Action Date for Barth Syndrome Application
April 29, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced
More news about: Stealth BioTherapeutics Inc.
Apr 29, 2025, 05:45 ET Shareholders that lost money on Sana Biotechnology, Inc.(SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 28, 2025, 21:00 ET Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin Regeneration and Wound Healing
also observed in skin tissue with epidermal damage caused by photoaging, as demonstrated in experiments conducted by Outer Biosciences Inc., a biotechnology company in Boston, MA, USA that researches ingredients for skin health. Byung-Fhy
More news about: Amorepacific
Apr 28, 2025, 20:05 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
April 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States
More news about: Pomerantz LLP
Apr 28, 2025, 18:55 ET Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a
More news about: Heron Therapeutics, Inc.
Apr 28, 2025, 16:01 ET AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Apr 28, 2025, 14:58 ET WACKER showcases binder technology for nonwoven products and solutions at IDEA2025
industries include healthcare, pharmaceuticals, cosmetics, construction, automotive, and food/nutrition. WACKER is a pioneer in silicone, polymer, and biotechnology solutions and the leading provider of polysilicon for semiconductor and solar applications. Media Contact:James
More news about: Wacker Chemical Corporation
Apr 28, 2025, 14:38 ET Prominent Life Sciences Partner Rejoins Latham's Bay Area Offices
firm's fantastic Healthcare & Life Sciences Practice," said Hillier. "Latham's unmatched global platform, depth of expertise in private equity, biotechnology, life sciences and healthcare, and collaborative culture provide the perfect environment for me to continue delivering exceptional service to clients
More news about: Latham & Watkins LLP
Apr 28, 2025, 14:15 ET INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
April 28, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States
More news about: Pomerantz LLP
Apr 28, 2025, 14:00 ET Myosin Therapeutics Awarded $3 Million NIH Grant to Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder
Fla., April 28, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing innovative therapies for cancer and neurological disorders, today announced that it has been awarded a $3
More news about: Myosin Therapeutics Inc.
Apr 28, 2025, 13:35 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive
More news about: THE ROSEN LAW FIRM, P. A.
Apr 28, 2025, 12:02 ET Rubin and Rudman Partner Jason Webber Named a 2025 "Go To Construction Lawyer" by Massachusetts Lawyers Weekly
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Apr 28, 2025, 10:30 ET Live Cell Imaging Market worth US$4.75 billion in 2030 with 8.68% CAGR | MarketsandMarkets™
growth is supported by the increasing investments in healthcare infrastructure, rising government support for life science research, and expanding biotechnology and pharmaceutical industries that are pushing the demand for advanced imaging technologies. India, China,
More news about: MarketsandMarkets
Apr 28, 2025, 10:05 ET AI In Healthcare Market Size to Reach $187.7 Billion by 2030 at CAGR 38.5% - Grand View Research, Inc.
Healthcare Providers (Hospitals, Outpatient Facilities, and Others)Healthcare PayersHealthcare Companies (Pharmaceutical, Biotechnology, Medical Devices)PatientsOthersAI In Healthcare Market - Regional Outlook (Revenue, USD Million, 2018 - 2030)
More news about: Grand View Research, Inc.
Apr 28, 2025, 08:33 ET GlycoNex Presents Preclinical Data on GNX1021 at AACR Annual Meeting 2025
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced the presentation of preclinical data on GNX1021, its
More news about: GlycoNex, Inc.
Apr 28, 2025, 08:30 ET Halozyme to Report First Quarter 2025 Financial and Operating Results
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Apr 28, 2025, 08:00 ET Celltrion to present six abstracts in inflammatory bowel disease (IBD) at 2025 Digestive Disease Week® (DDW)
Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information,
More news about: Celltrion
Apr 28, 2025, 07:30 ET Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Apr 28, 2025, 07:00 ET HERVolution Appoints Dr. Tine Gaziel as CMO to Advance Dark Genome-Targeting Immune Therapy into the Clinic
April 28, 2025 /PRNewswire/ -- HERVolution Therapeutics ApS ('HERVolution'), a dark genome-focused biotechnology company developing immunotherapies to address aging-related diseases, today announced Tine Gaziel, MD, PhD, has joined
More news about: HERVolution Therapeutics
Apr 28, 2025, 06:00 ET IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events
Yujiro S. Hata, President and Chief Executive Officer hosted by Gregory Renza, M.D., Director and Senior Biotechnology Research AnalystA live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events"
More news about: IDEAYA Biosciences, Inc.
Apr 28, 2025, 05:45 ET SANA LAWSUIT ALERT: The Gross Law Firm Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
More news about: The Gross Law Firm
Apr 28, 2025, 03:30 ET Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding
April 28, 2025 /PRNewswire/ -- Cycuria Therapeutics (Cycuria), a preclinical stage biotechnology company pioneering breakthrough protein-based targeted therapies for haematological cancers, today announces the formation of a distinguished Advisory
More news about: Cycuria Therapeutics
Apr 28, 2025, 02:30 ET Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update
www.oncoinvent.com. There will be a possibility for Q&A through the MS Teams Webinar. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide
More news about: Oncoinvent AS
Apr 28, 2025, 02:17 ET Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression
May 27 to April 30 at 11:00 CEST. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting
More news about: Oncoinvent AS